New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
07:02 EDTISISIsis Pharmaceuticals receives $15M milestone payment from AstraZeneca
Isis Pharmaceuticals announced that AstraZeneca has initiated a Phase 1 clinical study of ISIS-AR in patients with cancer. Isis earned a $15M milestone payment associated with the clinical advancement of ISIS-AR. ISIS-AR is an antisense drug designed to treat patients with prostate cancer by inhibiting the production of the androgen receptor. AstraZeneca is planning to develop ISIS-AR broadly to treat patients under a variety of settings during the course of prostate cancer treatment, including both as a single agent and in combination therapy.
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 16, 2014
07:06 EDTISISIsis Pharmaceuticals initiates phase 1/2 study of ISIS-DMPK Rx
Subscribe for More Information
December 11, 2014
09:28 EDTISISIsis Pharmaceuticals up 3% after CEO appears on Mad Money
Subscribe for More Information
December 8, 2014
10:41 EDTISISIsis Pharmaceuticals price target raised to $81 from $62 at Piper Jaffray
Subscribe for More Information
08:00 EDTISISIsis Pharmaceuticals price target raised to $66 from $55 at Stifel
Subscribe for More Information
05:30 EDTISISIsis Pharmaceuticals to host conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use